Keith Alcorn
Editorial Consultant, HIV, TB and Viral Hepatitis at Freelance
Historian of gardens, plant introductions and British botanical empire. Visiting tutor, @RHULHistory
Articles
-
4 weeks ago |
aidsmap.com | Keith Alcorn
Estimated reading time 5 minutes Young people who have been living with HIV since birth have a significant unmet need for innovative long-acting treatments that can overcome drug resistance and adherence challenges, a London study has concluded. These individuals should be a priority group for inclusion in clinical trials and implementation studies of long-acting treatments, the researchers say.
-
4 weeks ago |
aidsmap.com | Keith Alcorn
Estimated reading time 8 minutes Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people living with HIV, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
-
1 month ago |
aidsmap.com | Keith Alcorn
Estimated reading time 4 minutes There have been almost no scientific studies of the effectiveness of HIV pre-exposure prophylaxis (PrEP) in central or eastern Europe. However, a recent study of 887 PrEP users, all gay and bisexual men, in the Polish city of Wroclaw, found only nine HIV infections (1% of PrEP users) over a three-year period from 2020 to 2023. All 887 PrEP users took oral tenofovir disoproxil/emtricitabine (TDF/FTC) pills.
-
1 month ago |
aidsmap.com | Keith Alcorn
Estimated reading time 10 minutes While plans for global access to lenacapavir, the twice-yearly injectable PrEP product which demonstrated extraordinary efficacy last year, have progressed unusually quickly, critics say that the arrangements are riddled with inconsistencies and will not achieve Gilead Science’s stated goals of “ensuring broad, sustainable global access to lenacapavir for PrEP” and of “ending new HIV infections around the world”.
-
2 months ago |
aidsmap.com | Keith Alcorn
Estimated reading time 7 minutes Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective antiretroviral treatment, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 258
- Tweets
- 432
- DMs Open
- No
RT @SpotlightNSP: MUST READ | South Africa's worst crisis in 20 years could surpass COVID-19 and diabetes as a leading killer, while worsen…
RT @ByDonkeys: If Trump was President in 1940 https://t.co/4pS5JctgGv
RT @Kasparov63: Some truths seem eternal, like these from Lord Palmerston on Russian imperialism over 170 years ago! https://t.co/F1v0RYmcTs
